NSE headquarters with NSE IPO delay headline overlay and SEBI discussion

NSE IPO Delay | 9-Year Stalled Listing Forces NSE to Demand Urgent Finance Ministry Intervention

Posted on May 8, 2025, by Niftynews NSE IPO delay—a headline that has echoed through India’s financial markets for years—has now taken a new turn. The National Stock Exchange of India (NSE), the country’s largest stock exchange, has reached out to the Ministry of Finance, requesting it to intervene in its long-pending IPO, which remains stuck…

Read More
Most active NSE stocks today with highest trading volume

Top 10 Most Active NSE Stocks Today You Must Watch – April 24, 2025 Market Update

Posted on April 24, 2025, by Niftynews If you’re tracking momentum in the Indian stock market, keeping an eye on the most active NSE stocks today is critical. These high-volume movers often signal where investor interest lies, where short-term breakouts might happen, or where institutions are quietly shifting positions. As of 10:24 AM on April 24,…

Read More
BSE and NSE closure for Eid-Ul-Fitr on March 31, 2025

BSE and NSE Closed on March 31, 2025: Essential Stock Market Holiday Update You Can’t Miss!

Posted on March 28, 2025, by Niftynews The BSE and NSE will be closed on March 31, 2025, in observance of Eid-Ul-Fitr. Investors, traders, and market participants should prepare for this stock market holiday and plan their activities accordingly. This closure will affect all trading segments, including equities, derivatives, and securities lending and borrowing (SLB). Understanding…

Read More
PG Electroplast shares jump 11% on strong Q3 results PAT zooms 109% YoY, stock has jumped 300% in 12 months; check key details

PG Electroplast shares jump 11% on strong Q3 results; PAT zooms 109% YoY, stock has jumped 300% in 12 months; check key details

PG Electroplast Shares Surge 11% on Strong Q3 Results; PAT Soars 109% YoY PG Electroplast Ltd (PGEL), a key player in the consumer durables and electronic manufacturing services (EMS) sector, witnessed a sharp rally of 10.8%, with its share price climbing to ₹930.95 apiece on the BSE on Friday, February 7. This surge followed the…

Read More
Tata Motors share price declines 8% post Q3 results. Should you Buy, sell or hold the stock

Tata Motors share price declines 8% post Q3 results. Should you Buy, sell or hold the stock?

Tata Motors Shares Drop 8% After Q3 Earnings—Analysts React Tata Motors‘ stock took a hit on Thursday morning, sliding 8% after the company released its Q3 FY25 earnings post-market hours on Wednesday. While the Jaguar Land Rover (JLR) segment delivered solid results, the overall performance was weighed down by margin pressures. Tata Motors Q3 Earnings…

Read More
Kaynes Technology Share Price Slumps Over 19% As Management Cuts Fy25 Guidance Post Q3 Results

Kaynes Technology share price slumps over 19% as management cuts FY25 guidance post Q3 results

Kaynes Technology Shares Plunge 19% on Revised Revenue Guidance Kaynes Technology saw its share price tumble by over 19% on Tuesday following a downward revision in its revenue guidance for FY25. The company now projects revenue of ₹2,800 crore, down from its earlier estimate of ₹3,000 crore. What Led to the Drop? The sharp decline…

Read More
Denta Water And Infra Solutions Ipo Allotment Status Check Latest Gmp, Steps To Verify

Denta Water and Infra Solutions IPO Allotment Status: Check Latest GMP, Steps to Verify

Denta Water and Infra Solutions IPO Allotment Scheduled for Today, January 27, 2025 Denta Water and Infra Solutions Limited, a rising star in the water and infrastructure sector, is set to finalize its IPO allotment today. Founded in 2016, the company has quickly established itself as a key player in the industry, with expertise in…

Read More
Dr Reddy's Stock Plunges 6% As Revlimid Revenue Concerns Loom Large Despite Positive Q3 Earnings

Dr Reddy’s stock plunges 6% as Revlimid revenue concerns loom large despite positive Q3 earnings

Dr Reddy’s Faces Challenges with Revlimid Decline, But Opportunities Lie Ahead Dr Reddy’s Laboratories delivered Q3 earnings that slightly surpassed market expectations, but the spotlight was on the declining revenue from Revlimid, the company’s blockbuster cancer drug. Once a significant growth driver, Revlimid’s contribution to the company’s revenue has been shrinking as its patent expiry…

Read More
Back To Top